Impax Laboratories (IPXL) Misses Q2 EPS by 11c; Guides Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Impax Reports Second Quarter 2016 Financial Results
August 9, 2016 7:01 AM EDTHAYWARD, Calif., Aug. 9, 2016 /PRNewswire/ --Â Impax Laboratories, Inc. (NASDAQ: IPXL), a specialty pharmaceutical company, today reported second quarter 2016 financial results for the quarter ended June 30, 2016.
Logo - http://photos.prnewswire.com/prnh/20150310/180590LOGO
Total revenues in the second quarter 2016 declined 19% to $172.6 million, compared to $214.2 million in the prior year period. The decrease was primarily due to a 30% reduction in Generics division revenues which includes the impact of an approximate... More